Skip to content

Canadian nanomedicines in the spotlight: Molecular Pharmaceutics

A new special issue of the American Chemical Society journal Molecular Pharmaceutics highlights outstanding work related to contemporary nanomedicine research in Canada.

The issue, “Tiny Things, Huge Impact: Nanomedicine in Canada,”  was edited by NMIN researchers Dr. Shyh-Dar Li, Ellen Wasan, Marcel Bally, and Sarah Hedtrich, who contribute an editorial summarizing the core themes and drivers of the present research and providing context for future developments in the field.

The issue contains a range of articles that illustrate the breadth and global impact of research into the application of nanotechnology and nanomaterials for medical purposes currently under development in Canada.

“Canada’s leading position in nanomedicine innovation and
translation is evident,” write the editors. “Canadian scientists in nanomedicine have revolutionized modern medicine and brought novel therapies to treat diseases that were previously considered nonmanageable and improved the quality of life of patients globally.”

“In this issue, we explore not only traditional targets for nanodelivery such as tumors and the liver but also the skin and eyes … [and we share examples of how the field is] moving toward enhancing knowledge of biocompatibility, fine-tuning controlled release with smart and responsive polymers, and directing payload to specific cells in target organs.”

Other NMIN contributors to the issue include Pieter Cullis, Dominik Witzigmann, Miffy Cheng, Gang Zheng, Noorjahan Aibani, Kishor Wasan, Robert Hancock, Afsaneh Lavasanifar, Lisa Silverman, Po-Han Chao, Anna Blakney, and Warren Chan.